ITCC-077 NAXITAMAB
A Pivotal Phase 2 Trial of Antibody Naxitamab (hu3F8) and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone/Bone Marrow
Promotor Name : Y-mAbs THERAPEUTICS
Investigator Name : B. KUSHNER
Trial registered on clinicaltrial.gov: NCT03363373
